Capsule Summaries

Share

Program Content

Activities

  • TB Prevention With 3HP vs 6H
    3-Mo Rifapentine and Isoniazid vs 6-Mo Isoniazid TB Preventive Therapy in People Living With HIV in Western Kenya
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 12, 2025

    Expires: September 11, 2025

  • MK8591A052 Phase III Trial of DOR and ISL
    MK-8591A-052: Phase III Trial of Switch From BIC/FTC/TAF to DOR/ISL in People Living With Virologically Suppressed HIV
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 12, 2025

    Expires: September 11, 2025

  • MK8591A051
    MK-8591A-051: Phase III Trial of Switch From Standard-of-Care ART to DOR/ISL in People Living With Virologically Suppressed HIV
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 13, 2025

    Expires: September 12, 2025

  • CARES 96 Wk
    CARES: 96-Wk Efficacy and Safety of LA CAB + RPV in Sub-Saharan Africa
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 13, 2025

    Expires: September 12, 2025

  • PILLAR
    PILLAR: Efficacy and Persistence of Long-Acting Cabotegravir in Real-world Phase IV Trial of HIV PrEP
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 13, 2025

    Expires: September 12, 2025

  • PURPOSE 1 Adolescent Women
    PURPOSE 1: Lenacapavir PrEP in Adolescent Cisgender Women
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 14, 2025

    Expires: September 13, 2025

  • Lenacapavir, Teropavimab, and Zinlirvimab
    Phase II Study Results of Lenacapavir, Teropavimab, and Zinlirvimab for People Living with Virologically Suppressed HIV
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 14, 2025

    Expires: September 13, 2025

  • On Demand PrEP for Women
    Utilizing PK/PD Modeling to Optimize On-Demand TDF/FTC PrEP Dosing for Women
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 14, 2025

    Expires: September 13, 2025

  • DoxyPEP for STI Prevention
    Doxycycline Postexposure Prophylaxis for STI Prevention in People on HIV PrEP Presenting for Sexual Health Visits
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 14, 2025

    Expires: September 13, 2025

  • STOMP Tecovirimat
    Phase III STOMP: Tecovirimat for the Treatment of Clade II Mpox
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 17, 2025

    Expires: September 16, 2025

  • HPTN 094
    HPTN 094: Mobile Unit Services Plus Peer Health Navigation vs Peer Health Navigation Alone for People Who Inject Drugs
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 17, 2025

    Expires: September 16, 2025

  • BEe HIVe
    BEe-HIVe: HepB-CpG HBV Vaccine Durability in People Living With HIV on ART ± Prior Vaccine History
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 17, 2025

    Expires: September 16, 2025

  • HPTN 084 OLE
    HPTN 084 OLE: HIV-1 RNA Screening in Women Receiving Long-Acting Cabotegravir for PrEP
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 17, 2025

    Expires: September 16, 2025

  • Semaglutide in HIV
    Semaglutide in People Living With HIV: Effect on Cognitive Function
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 17, 2025

    Expires: September 16, 2025

  • HPTN 083 Case Series
    HPTN 083 Case Series: Treatment Outcomes Among People Who Acquired HIV During LA CAB PrEP
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 18, 2025

    Expires: September 17, 2025

  • RIO
    RIO: Phase II Study Evaluating bNAbs for HIV Viremia Control
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 18, 2025

    Expires: September 17, 2025

Provided by

ProCE Banner

Supporters

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare